NEW YORK (Reuters) - U.S. health regulators have approved a second company to market a generic version of the pain patch Duragesic, turning the table on generic drugmaker Mylan Laboratories Inc. (NYSE:MYL - news), which on Monday predicted it would have no rivals through March. The news sent shares of Mylan, which had been the only drugmaker approved to sell the treatment, down 15 percent.
